Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2023-12-22 Legal Proceedings Report
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform that the Company has received a draft order for the assessment unit being passed under Section 144C(1) ....
Legal Proceedings Report Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to stock exchanges. It informs about a draft order related to tax assessment and transfer pricing issues, including financial implications. The document is a regulatory announcement about a legal/tax matter, not a full audit report or annual report. It includes details of a dispute and expected financial impact but does not contain comprehensive financial statements or detailed audit results. This fits the category of Legal Proceedings Report (LTR), as it updates on significant legal/tax disputes involving the company.
2023-12-22 English
Updates
Legal Proceedings Report Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, addressed to stock exchanges. It informs about a draft order related to tax assessment and transfer pricing issues, including financial implications. The document includes details of a legal dispute and the company's intention to challenge the order. It is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about a legal proceeding and its potential financial impact. The document is short (2967 characters) and serves as a notification to the stock exchanges, fitting the description of a Legal Proceedings Report (LTR).
2023-12-22 English
Appointment
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges regarding the appointment of an additional director to the company's board. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in the board or management. The content includes details about the new director's appointment date, profile, and relationship disclosures. There are no financial statements, earnings data, or report attachments. The document is clearly an announcement of a board/management change rather than a full report or other filing type.
2023-12-21 English
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors ....
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges regarding the appointment of an additional director to the company's board. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in the board or management. The content includes details about the new director's appointment date, profile, and relationship disclosures. There are no financial statements, earnings data, or report attachments. The document is clearly an announcement of a board/management change rather than a full report or other filing type.
2023-12-21 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges (BSE and NSE) regarding the launch of a pharmaceutical product, Trastuzumab deruxtecan (Enhertu), by AstraZeneca Pharma India Limited. It references a prior communication about regulatory approval and provides an update on the product launch date. The document is brief (1385 characters), does not contain financial data, financial results, or detailed report content. It is an announcement to take the information on record rather than a full report or detailed filing. There is no indication of financial statements, audit information, management discussion, or regulatory certifications. Therefore, it fits best as a Regulatory Filing (RNS), which is a general category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-20 English
We refer to earlier communication dated May 3, 2023 intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Tanstuzumab deruxtecan ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) announcing the launch of a pharmaceutical product, Trastuzumab deruxtecan (Enhertu), by AstraZeneca Pharma India Limited. It references a prior communication about regulatory approval (Form CT-20) and provides an update on the product launch date. The content is an announcement related to a product launch and regulatory permissions, not a financial report, earnings release, or management discussion. It does not contain financial data, voting results, or governance information. The document is short (1385 characters) and serves as a regulatory announcement to stock exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-12-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.